Results 281 to 290 of about 1,745,820 (365)

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Exploring the nanobody patent landscape: a focus on BCMA sequences and structural analysis. [PDF]

MAbs
Xu J, Wang Y, Yuan N, Hu G, Hu Y.
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

FRAND and Other Requirements in China's Announcement on Releasing (Provisional) Administration Regulations of National Standards Involving Patents

, 2014
Dan Prud’homme
openalex   +1 more source

Protein O‐glycosylation in the Bacteroidota phylum

FEBS Open Bio, EarlyView.
Species of the Bacteroidota phylum exhibit a unique O‐glycosylation system. It modifies noncytoplasmic proteins on a specific amino acid motif with a shared glycan core but a species‐specific outer glycan. A locus of multiple glycosyltransferases responsible for the synthesis of the outer glycan has been identified.
Lonneke Hoffmanns, Dennis Svedberg, André Mateus   +2 more
wiley   +1 more source

Predictors of recurrent ischemic stroke: anatomical characteristics of patent foramen ovale. [PDF]

Front Cardiovasc Med
Chen X, Fang J, Yang Q, Liu L.
europepmc   +1 more source

Actin dynamics controlled by IqgC, a RasGAP at the crossroads between the IQGAP and fungal GAP1 families

FEBS Open Bio, EarlyView.
IqgC is a RasGAP from Dictyostelium discoideum. IqgC binds RasG via its RasGAP domain and deactivates it on macroendocytic cups, thereby suppressing the uptake of fluid and particles. IqgC has a positive effect on cell‐substratum adhesion, and its RGCt domain is required for recruitment to ventral foci.
Vedrana Filić, Darija Putar, Lucija Mijanović, Igor Weber   +3 more
wiley   +1 more source

Early protocol-based echocardiographic assessment and management of patent ductus arteriosus in infants less than 29 weeks' gestation. [PDF]

BMJ Paediatr Open
Homedi A, Mandurah A, Alamer F, Alkaabi M, Bazbouz E, Alharbi F, Alamoudi B, Alshreedah S, Alwatban A, Alsaif S, Ali K.   +10 more
europepmc   +1 more source

Key role for inhibins in effective T cell activation, migration and Th17 differentiation

FEBS Open Bio, EarlyView.
Activins/inhibins modulate immune responses. Here, we show that inhibins can be produced very early after T cell activation and can act in an autocrine way, favoring Th1 versus Th17 differentiation and CCL19/CCL21 mediated migration. Recombinant inhibin A can restore the Th1/Th17 balance, highlighting the role of inhibins as key regulators of T cell ...
Sandra Ortega‐Francisco, Roxana Olguín‐Alor, Lizbeth Bolaños‐Castro, Alexandra Morales‐Cruz, Marisol De La Fuente‐Granada, Gloria Soldevila   +5 more
wiley   +1 more source